MEDIDATA

MID-SIZED AND EMERGING BIOPHARMA

THE TECHNOLOGY AND EXPERTISE TO SUCCEED

In a highly competitive industry, how you apply your finite resources to accelerate outcomes is critical. Medidata's 20+ years of expertise with customers and trials of all sizes can help you stay on the path to success. Mitigate risk by managing your data and workflows in one place with proven innovative technology supported by a trusted partner at the center of the life sciences ecosystem.

Together with your CRO, we can achieve our collective mission of extending greater value to patients and realizing the best possible outcome of trials.

WHY DO MID-SIZED AND EMERGING BIOPHARMA COMPANIES TRUST MEDIDATA FOR SUCCESS?

Tested on over...

2.6K Single Site Studies

3K Phase 1 Studies

20K Trials

Trusted by...

180+ CRO Partners

1.2K Emerging and Mid-Sized Biopharma Companies

900K+ Site and Sponsor Relationships

A Unified Platform for Studies of Every Size



Visit medidata.com/mid-sized-biopharma to learn more.



Mid-sized and emerging companies need a competitive edge.

Medidata uses industry best practices from over 1.2K emerging and mid-sized biopharma companies like you to ensure efficient deployment and faster technology adoption to allow you and your trials to advance with agility and speed.

ONCONOVA THERAPEUTICS

"A lot of sites were happy to hear we were going over to Medidata."

Patrick Zbyszewski, Director of Clinical Data Management

CHALLENGE

- Difficulty screening patients due to unpredictable eligibility criteria for rare indication qualifications of studies

SOLUTION

- Initial selection of Rave EDC and Rave Coder
- Based on success of platform and company growth, Rave RRTSM and Rave Targeted SDV introduced

BOTTOM LINE

- Platform offered flexible control over study build and design, allowing Onconova to employ a variety of different models based on available resources and costs
- Reduced costs of contracting third-party builders
- Standardized study build eliminated protocol redundancies and reduced trial start-up time

CANCER RESEARCH UK

"Everything is there in one place. We can filter by site, we can filter by what's been dispensed, and it's really easy for us to track."

Olivia Frank, Clinical Research Associate

CHALLENGE

- Randomizing trial subjects
- Drug supply management

SOLUTION

- Integration of Rave RTSM with Rave EDC enabled seamless monitoring

BOTTOM LINE

- Intuitive user interface led to reduced training time and faster access to data
- Product integration easier than originally thought
- Faster study start-up

MEDICENNA™

"Medicenna, as a small company, we [got support from the FDA for] the very first design of a Phase 3 registration trial where the majority of patients would come from a Synthetic Control Arm®."

Fahar Merchant, CEO, Medicenna

CHALLENGE

- Patient recruitment and retention for recurrent glioblastoma (rGBM) patients due to the possibility of being place in control arm

SOLUTION

- Synthetic control arm (SCA®) formed by carefully selecting patients from historical clinical trials to match the demographic and disease characteristics of patients treated with the new investigational product

BOTTOM LINE

- Precedent-setting agreement from the FDA to design a Phase 3 registrational trial using a hybrid-SCA
- Will reduce the number of patients assigned the control arm while still providing scientifically rigorous data
- Accelerate trial timelines, lower costs and enable faster product development

Visit medidata.com/mid-sized-biopharma to learn more.

MEDIDATA